Brief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
25/05/2026 02:50
May 25 (Reuters) - Argent BioPharma Ltd RGT.AX: LONG TERM AQUIOL LICENSING AND SUPPLY AGREEMENT ENTERS LONG-TERM LICENSING AND SUPPLY AGREEMENT WITH THE SKIN HEALTH INSTITUTE AGREEMENT INCLUDES €3,000 MONTHLY ROYALTY PLUS 5% REVENUE-LINKED ROYALTY AGREEMENT GRANTS EXCLUSIVE WORLDWIDE USE OF AQUIOL FOR DERMATOLOGY COSMETIC APPLICATIONS ESTABLISHES LONG-TERM SUPPLY ARRANGEMENT FOR SHI TO SOURCE AQUIOL FROM ARGENT BIOPHARMA AGREEMENT INCLUDES COLLABORATION PROVISIONS FOR U.S. DERMATOLOGY AND COSMETIC MARKETS Further company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group